{"product_id":"human-fgf-21-protein-bhp13700137","title":"Human FGF 21 Protein","description":"\u003ch2\u003eBackground\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eFGF\u003c\/strong\u003e is supplied as a recombinant protein reagent for \u003cstrong\u003eresearch use only\u003c\/strong\u003e. In RUO settings, recombinant proteins provide defined inputs for biochemical assays, interaction mapping, and assay development where control over protein identity and concentration supports reproducibility.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eAlso known as:\u003c\/strong\u003e Fibroblast Growth Factor 21; FGF-21; FGF21.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eSpecies origin:\u003c\/strong\u003e Human.\u003c\/p\u003e\u003cp\u003eHuman FGF21 protein, expressed in E. coli\u003c\/p\u003e\u003cp\u003eEndotoxin: \u0026lt; 1 EU per μg of the protein as determined by the LAL method\u003c\/p\u003e\u003ch2\u003eBiological significance and function\u003c\/h2\u003e\u003cp\u003eFunctionally, \u003cstrong\u003eFGF\u003c\/strong\u003e mediates intercellular communication in immune and stress-response settings through receptor engagement and downstream transcriptional programs. Experimental systems often use defined protein inputs to disentangle receptor proximal signaling from later transcriptional responses. This target is frequently investigated in research themes such as \u003cstrong\u003eOncology \u0026amp; Angiogenesis\u003c\/strong\u003e.\u003c\/p\u003e\u003ch2\u003eMolecular characteristics\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eMolecular characteristics:\u003c\/strong\u003e Protein domains, oligomeric state, and modification-sensitive surfaces can influence binding behavior and functional readouts in vitro. Where relevant, isoforms and PTMs may alter activity, stability, or interaction specificity.\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eSource species:\u003c\/strong\u003e Human\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMolecular weight:\u003c\/strong\u003e 19.4 kDa\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eProtein length:\u003c\/strong\u003e The recombinant Human FGF21 consists of 181 amino acids and has a predicted molecular mass of 19.4 kDa. The apparent molecular mass of the Human FGF21 protein is approximately 19.4 kDa in SDS-PAGE under reducing conditions\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eExpression region:\u003c\/strong\u003e Amino acid sequence derived from Human FGF21 isoform(Q9NSA1)(His29-Ser209) was expressed.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e ≥ 98 % as determined by SDS-PAGE\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eBiological activity:\u003c\/strong\u003e Testing in progress\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003e\u003cstrong\u003ePost-translational considerations:\u003c\/strong\u003e E. coli expression typically yields a non-glycosylated recombinant form. This is often suitable for many intracellular enzymes and binding studies, while PTM-dependent targets may show differences when glycosylation or specific disulfide-bond patterns are required. For many extracellular signaling proteins and proteases, disulfide bonding and glycosylation can be important for stability and activity.\u003c\/p\u003e\u003ch2\u003eExpression and purification strategy\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eExpression system:\u003c\/strong\u003e E. coli. Expression system selection can influence folding state and PTM profile, which may affect binding or activity for PTM-sensitive targets.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eTagging:\u003c\/strong\u003e No tag tags are commonly used to streamline purification and enable capture\/immobilization in interaction assays. Tag presence or removal can influence some binding measurements depending on assay design.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eFormulation:\u003c\/strong\u003e Lyophilized from sterile 20 mM Tris, 150 mM NaCl pH 8.0.. Formulation and buffer composition can influence stability, aggregation propensity, and assay background in downstream biochemical experiments.\u003c\/p\u003e\u003ch2\u003eResearch interpretation\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eResearch interpretation:\u003c\/strong\u003e Cytokine-driven outcomes depend on receptor availability, timing, and crosstalk with stress and metabolic pathways. Defined protein inputs help disentangle receptor-proximal signaling from downstream transcriptional and phenotypic responses.\u003c\/p\u003e","brand":"Abbkine Scientific Co., Ltd.","offers":[{"title":"5 ug","offer_id":52997739774317,"sku":"PRP1030-5UG","price":89.0,"currency_code":"USD","in_stock":true},{"title":"50 ug","offer_id":52997739807085,"sku":"PRP1030-50UG","price":189.0,"currency_code":"USD","in_stock":true},{"title":"500 ug","offer_id":52997739839853,"sku":"PRP1030-500UG","price":909.0,"currency_code":"USD","in_stock":true},{"title":"1 mg","offer_id":52997739872621,"sku":"PRP1030-1MG","price":1369.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/PRP1030.png?v=1770191177","url":"https:\/\/www.ebiohippo.com\/products\/human-fgf-21-protein-bhp13700137","provider":"BioHippo","version":"1.0","type":"link"}